Anti-HSPA1L Polyclonal Antibody for WB - P34931

Core Product Specifications and Parameters

Biological Background: HSPA1L Function and Localization

• HSPA1L, also known as HSP70-Hom or heat shock 70 kDa protein 1-like, is a member of the heat shock protein 70 (HSP70) family.
• Functions as a molecular chaperone involved in protein quality control, facilitating correct folding, re-folding, and degradation of misfolded proteins.
• Its chaperone activity is regulated by ATP-binding and hydrolysis cycles, with low substrate affinity in the ATP-bound state and high affinity in the ADP-bound state. Related references: PMID:26865365
• Positively regulates PRKN (parkin) translocation to damaged mitochondria, contributing to mitophagy. Related references: PMID:24270810
• Exhibits ATP-binding and nucleotide-binding properties.
• Expressed specifically in spermatids, suggesting a role in spermatogenesis.
• The protein has been identified in proteomics studies and its 3D structure has been determined.

Experimental Guidance and Technical Tips

• The immunogen corresponds to a C-terminal fragment (aa 342-641), which may be suitable for detecting both native and denatured HSPA1L in WB. Consider using appropriate lysis buffers and loading controls.
• For WB, a band around 70 kDa is expected; validate the antibody in relevant human and mouse samples per documented cross reactivity.
• In ELISA, consider using this polyclonal antibody as a capture or detection reagent, with appropriate optimization of coating and blocking conditions.
• When analyzing spermatid-related samples, include appropriate tissue-specific positive controls to confirm target expression.

CamelBio: Your One-Stop Sourcing Bridge

As a dedicated IVD raw material supplier, CamelBio provides diagnostic manufacturers and research laboratories with one-stop access to validated antibodies like this anti-HSPA1L polyclonal antibody, supporting protein chaperone, proteostasis, and reproductive biology research. Beyond individual reagents, we offer antibody pairs, optimized polyclonal and monoclonal antibodies, bulk ancillary reagents, and sourcing services for rare targets—streamlining your transition from concept to clinical application.